217 related articles for article (PubMed ID: 37134157)
21. Reprogramming of human γδ T cells by expression of an anti-CD19 TCR fusion construct (εTRuC) to enhance tumor killing.
Juraske C; Krissmer SM; Teuber ES; Parigiani MA; Strietz J; Wesch D; Kabelitz D; Minguet S; Schamel WW
J Leukoc Biol; 2024 Jan; 115(2):293-305. PubMed ID: 38149982
[TBL] [Abstract][Full Text] [Related]
22. MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.
Zhai X; You F; Xiang S; Jiang L; Chen D; Li Y; Fan S; Han Z; Zhang T; An G; Zhang B; Chen Y; Meng H; Yang L
Am J Cancer Res; 2021; 11(1):79-91. PubMed ID: 33520361
[TBL] [Abstract][Full Text] [Related]
23. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
Narayan V; Barber-Rotenberg JS; Jung IY; Lacey SF; Rech AJ; Davis MM; Hwang WT; Lal P; Carpenter EL; Maude SL; Plesa G; Vapiwala N; Chew A; Moniak M; Sebro RA; Farwell MD; Marshall A; Gilmore J; Lledo L; Dengel K; Church SE; Hether TD; Xu J; Gohil M; Buckingham TH; Yee SS; Gonzalez VE; Kulikovskaya I; Chen F; Tian L; Tien K; Gladney W; Nobles CL; Raymond HE; ; Hexner EO; Siegel DL; Bushman FD; June CH; Fraietta JA; Haas NB
Nat Med; 2022 Apr; 28(4):724-734. PubMed ID: 35314843
[TBL] [Abstract][Full Text] [Related]
24. Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells
Wang S; Li H; Ye C; Lin P; Li B; Zhang W; Sun L; Wang Z; Xue D; Teng W; Zhou X; Lin N; Ye Z
Front Immunol; 2018; 9():377. PubMed ID: 29535738
[TBL] [Abstract][Full Text] [Related]
25. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for castration-resistant prostate cancer: has its time arrived?
Slovin SF
Expert Opin Biol Ther; 2020 May; 20(5):481-487. PubMed ID: 32097050
[No Abstract] [Full Text] [Related]
27. Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer.
Teng KY; Mansour AG; Zhu Z; Li Z; Tian L; Ma S; Xu B; Lu T; Chen H; Hou D; Zhang J; Priceman SJ; Caligiuri MA; Yu J
Gastroenterology; 2022 Apr; 162(4):1319-1333. PubMed ID: 34999097
[TBL] [Abstract][Full Text] [Related]
28. Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer.
Wang A; Lv T; Song Y
Cell Immunol; 2023; 391-392():104760. PubMed ID: 37660477
[TBL] [Abstract][Full Text] [Related]
29. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
Front Immunol; 2020; 11():1347. PubMed ID: 32714329
[TBL] [Abstract][Full Text] [Related]
30. Dysregulated CD25 and Cytokine Expression by γδ T Cells of Systemic Sclerosis Patients Stimulated With Cardiolipin and Zoledronate.
Migalovich Sheikhet H; Villacorta Hidalgo J; Fisch P; Balbir-Gurman A; Braun-Moscovici Y; Bank I
Front Immunol; 2018; 9():753. PubMed ID: 29706966
[TBL] [Abstract][Full Text] [Related]
31. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
Autio KA; Higano CS; Nordquist L; Appleman LJ; Zhang T; Zhu XH; Babiker H; Vogelzang NJ; Prasad SM; Schweizer MT; Madan RA; Billotte S; Cavazos N; Bogg O; Li R; Chan K; Cho H; Kaneda M; Wang IM; Zheng J; Tang SY; Hollingsworth R; Kern KA; Petrylak DP
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36948505
[TBL] [Abstract][Full Text] [Related]
32. Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
Izumi H; Yamasaki A; Takeda K; Kodani M; Touge H; Tanaka N; Yanai M; Ueda Y; Sakamoto T; Nishii-Ito S; Makino H; Yamaguchi K; Igishi T; Shimizu E
Lung Cancer; 2018 Aug; 122():200-205. PubMed ID: 30032832
[TBL] [Abstract][Full Text] [Related]
33. Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S; Chevalier MF; Benmerzoug S; Cesson V; Schneider AK; Rodrigues-Dias SC; Dartiguenave F; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002184
[No Abstract] [Full Text] [Related]
34. Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.
Liu Z; Guo BL; Gehrs BC; Nan L; Lopez RD
J Urol; 2005 May; 173(5):1552-6. PubMed ID: 15821484
[TBL] [Abstract][Full Text] [Related]
35. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
36. A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
Baek DS; Kim YJ; Vergara S; Conard A; Adams C; Calero G; Ishima R; Mellors JW; Dimitrov DS
Cancer Lett; 2022 Jan; 525():97-107. PubMed ID: 34740610
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models.
Nishimoto KP; Barca T; Azameera A; Makkouk A; Romero JM; Bai L; Brodey MM; Kennedy-Wilde J; Shao H; Papaioannou S; Doan A; Masri C; Hoang NT; Tessman H; Ramanathan VD; Giner-Rubio A; Delfino F; Sharma K; Bray K; Hoopes M; Satpayev D; Sengupta R; Herrman M; Abbot SE; Aftab BT; An Z; Panuganti S; Hayes SM
Clin Transl Immunology; 2022; 11(2):e1373. PubMed ID: 35136603
[TBL] [Abstract][Full Text] [Related]
38. Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy.
Jiang Y; Wen W; Yang F; Han D; Zhang W; Qin W
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205714
[TBL] [Abstract][Full Text] [Related]
39. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
40. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
